Key Drivers
- Margin strength
- Cash generation
- Debt burden
AIAI Summary
GILD is shifting from a mature HIV cash generator to a broader biotech transition story, but the stock will likely stay range-bound until Yeztugo uptake, oncology assets, and acquisition execution prove they can offset patent and exclusivity decay.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Cash generation
- •Debt burden
GILD delivers strong margins and cash flow with solid returns on capital, but its leverage, heavy intangibles, and above-average valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Support Holding
- •Lower Highs
- •Resistance Stalled
GILD has drifted lower over the last month, holding near $128–$129 support but repeatedly failing in the $133–$136 resistance zone, so the near-term bias remains range-bound to bearish unless it reclaims resistance.
క
Rebounded from $127.75 on 2026-04-27 to $136.30 on 2026-05-06 before fading
Sentiment & News
Key News Insights:
- •HIV Momentum
- •Oncology Expansion
- •EPS Pressure
Gilead is drawing bullish attention for its HIV and oncology growth story, but a lower 2026 EPS outlook, higher costs, and cell therapy headwinds are tempering near-term upside.
The stock looks constructive for long-term investors, but short-term trading may stay volatile until guidance and margin concerns improve
Similar Companies in Healthcare
Other companies in the same sector with AI ratings